#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Propionic acidaemia Ependymoma Arteriovenous malformation Acute graft versus host disease Familial hypertriglyceridaemia Epstein-Barr virus associated lymphoproliferative disorder Fungal infection Familial amyotrophic lateral sclerosis Neuronal ceroid lipofuscinosis Inflammatory myofibroblastic tumour Cystic fibrosis Juvenile idiopathic arthritis Enteritis Congenital cystic kidney disease Neuroendocrine carcinoma More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Diagnostics Rhabdomyosarcoma – Life with Disease Hairy cell leukaemia recurrent Fragile X syndrome – Trials in Disease Cholangitis sclerosing – Basic Information Breast angiosarcoma – Life with Disease Angiosarcoma metastatic – Life with Disease Glycogen storage disease type I – Diagnostics Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment Sarcoidosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Clofazimine XMAB942 Etrasimod Arginine Savolitinib Trastuzumab Anhydrous Cyclophosphamide Ifosfamide Arginine Teplizumab Pertechnetate (99Mtc) Sodium Trientine Dihydrochloride Bi 1015550 Dexrazoxane Tazobactam Remibrutinib Adezunap AP31969 SULFATE Ponatinib Tecaginlimab Taxanes More therapies…

    Learn about Your Condition

    Adenovirus infection Bacterial prostatitis Cataract Cervical dysplasia Erythema Pulmonary embolism Biliary cancer metastatic Delayed graft function Hypochromic anaemia Multifocal motor neuropathy Acute lymphocytic leukaemia Metastasis Corneal graft rejection Loeys-Dietz syndrome Electronic cigarette user More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • A study to evaluate the effectiveness of NAV-240 in adults with moderate-to-severe hidradenitis suppurativa

    Recruiting

    2 1 1
    Investigated Diseases:
    • Connective tissue disorder
    • Dermatitis
    • Hidradenitis
    Investigated Drugs:
    • IMB 101
    • Sodium Chloride
    Bulgaria Germany Hungary Poland Romania

  • A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

    Recruiting

    3 1 1
    Investigated Drugs:
    • Lebrikizumab
    Bulgaria France Germany Italy Poland Spain

  • A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis

    Recruiting

    2 1 1
    France Germany Greece Italy Poland Spain

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Capecitabine
    Austria Belgium Czechia France Germany Italy +5

  • A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

    Recruiting

    4 1 1
    Investigated Drugs:
    • Kyv-101
    Germany
Previous Page
1 … 643 644 645 646 647 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!